We are live on ! Find out more
IMDX

Insight Molecular Diagnostics
IMDX

65 hedge funds and large institutions have $47M invested in Insight Molecular Diagnostics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 23 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.11% less ownership

Funds ownership: 2.9% → 2.79% (-0.11%)

13% less funds holding

Funds holding: 75 → 65 (-10)

21% less capital invested

Capital invested by funds: $59.4M → $47M (-$12.3M)

57% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 23

64% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 14

Holders
65
Holders Change
-10
Holders Change %
-13.33%
% of All Funds
1.12%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
5
Increased
10
Reduced
23
Closed
14
Calls
$52K
Puts
–
Net Calls
+$52K
Net Calls Change
-$104K

Top Buyers

Rank Fund Capital Flow
1
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$36.4K
2
Ameriprise
Ameriprise
Minnesota
+$27.8K
3
Jane Street
Jane Street
New York
+$26.6K
4
LPL Financial
LPL Financial
California
+$26K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$18.7K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$827K
2
Millennium Management
Millennium Management
New York
-$238K
3
Citadel Advisors
Citadel Advisors
Florida
-$194K
4
SSA
Schonfeld Strategic Advisors
New York
-$180K
5
E
Ergoteles
New York
-$145K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Broadwood Capital
New York
$17M – – –
PVI
2
Pura Vida Investments
New York
$13.2M – – –
AIC
3
AWM Investment Company
New York
$5.66M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$3.18M +$8.79K +508 +0.2%
DC
5
Defender Capital
North Carolina
$1.88M -$32.4K -1,870 -1%
BlackRock
6
BlackRock
New York
$1.68M -$33K -1,904 -2%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$726K +$18.7K +1,082 +2%
SSA
8
Schonfeld Strategic Advisors
New York
$547K -$180K -10,385 -22%
Millennium Management
9
Millennium Management
New York
$527K -$238K -13,739 -28%
PM
10
Penbrook Management
New York
$411K -$10.7K -620 -2%
Goldman Sachs
11
Goldman Sachs
New York
$279K -$139K -8,022 -30%
ACM
12
ACT Capital Management
Pennsylvania
$241K – – –
State Street
13
State Street
Massachusetts
$206K -$39.2K -2,265 -14%
Northern Trust
14
Northern Trust
Illinois
$152K – – –
BCM
15
Bridgeway Capital Management
Texas
$150K – – –
IA
16
IFP Advisors
Florida
$106K – – –
LPL Financial
17
LPL Financial
California
$101K +$26K +1,501 +28%
FSA
18
Fort Sheridan Advisors
Illinois
$99K – – –
Morgan Stanley
19
Morgan Stanley
New York
$80K -$33.8K -1,955 -26%
CWMU
20
Caliber Wealth Management (Utah)
Utah
$55K – – –
Deutsche Bank
21
Deutsche Bank
Germany
$49K – – –
E
22
Ergoteles
New York
$47K -$145K -8,392 -72%
Bank of America
23
Bank of America
North Carolina
$46K -$47.3K -2,733 -46%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$46K – – –
Charles Schwab
25
Charles Schwab
California
$46K – – –
1
2 3

IMDX Hedge Fund Activity: Q3 2022 in Review

65 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q3 2022, worth a combined $47M — down 21% from $59.4M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of IMDX and 5 opened new positions — a net loss of 9 holders — while 23 trimmed existing stakes and 10 added.

The largest buyer was Balyasny Asset Management, adding an estimated $36.4K. The largest seller was OrbiMed, cutting an estimated $827K.

  • 65 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q3 2022, down from 75 in Q2 2022.
  • Funds reported $47M of Insight Molecular Diagnostics stock for Q3 2022, down 21% quarter-over-quarter.
  • 5 funds opened new Insight Molecular Diagnostics positions in Q3 2022 and 14 closed out, a net change of -9 holders.
  • The largest Insight Molecular Diagnostics buyer in Q3 2022 was Balyasny Asset Management, an estimated $36.4K added.
  • The largest Insight Molecular Diagnostics seller in Q3 2022 was OrbiMed, an estimated $827K sold.

Based on aggregated 13F filings for Q3 2022.